135 related articles for article (PubMed ID: 23357307)
1. Novel pyrazole derivatives as neutral CB₁ antagonists with significant activity towards food intake.
Manca I; Mastinu A; Olimpieri F; Falzoi M; Sani M; Ruiu S; Loriga G; Volonterio A; Tambaro S; Bottazzi ME; Zanda M; Pinna GA; Lazzari P
Eur J Med Chem; 2013 Apr; 62():256-69. PubMed ID: 23357307
[TBL] [Abstract][Full Text] [Related]
2. Prospective therapeutic agents for obesity: molecular modification approaches of centrally and peripherally acting selective cannabinoid 1 receptor antagonists.
Sharma MK; Murumkar PR; Kanhed AM; Giridhar R; Yadav MR
Eur J Med Chem; 2014 May; 79():298-339. PubMed ID: 24747288
[TBL] [Abstract][Full Text] [Related]
3. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
[TBL] [Abstract][Full Text] [Related]
4. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and pharmacological evaluation of novel 4-alkyl-5-thien-2'-yl pyrazole carboxamides.
Lazzari P; Pau A; Tambaro S; Asproni B; Ruiu S; Pinna G; Mastinu A; Curzu MM; Reali R; Bottazzi ME; Pinna GA; Murineddu G
Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):254-76. PubMed ID: 22931442
[TBL] [Abstract][Full Text] [Related]
6. Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands.
Murineddu G; Asproni B; Corona P; Piras S; Lazzari P; Ruiu S; Legnani L; Toma L; Pinna GA
Molecules; 2019 Apr; 24(9):. PubMed ID: 31035548
[TBL] [Abstract][Full Text] [Related]
7. Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands.
Pinna G; Loriga G; Lazzari P; Ruiu S; Falzoi M; Frau S; Pau A; Murineddu G; Asproni B; Pinna GA
Eur J Med Chem; 2014 Jul; 82():281-92. PubMed ID: 24922543
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of new N-alkyl 1-aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamides as cannabinoid receptor ligands.
Silvestri R; Ligresti A; La Regina G; Piscitelli F; Gatti V; Lavecchia A; Brizzi A; Pasquini S; Allarà M; Fantini N; Carai MA; Bigogno C; Rozio MG; Sinisi R; Novellino E; Colombo G; Di Marzo V; Dondio G; Corelli F
Eur J Med Chem; 2010 Dec; 45(12):5878-86. PubMed ID: 20943290
[TBL] [Abstract][Full Text] [Related]
10. Pentacycle derivatives as cannabinoid CB1 receptor ligands.
Lee SH; Seo HJ; Kim MJ; Kang SY; Lee SH; Ahn K; Lee M; Han HK; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Dec; 19(23):6632-6. PubMed ID: 19850473
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, hypoglycemic activity and molecular modeling studies of pyrazole-3-carbohydrazides designed by a CoMFA model.
Hernández-Vázquez E; Aguayo-Ortiz R; Ramírez-Espinosa JJ; Estrada-Soto S; Hernández-Luis F
Eur J Med Chem; 2013 Nov; 69():10-21. PubMed ID: 23995214
[TBL] [Abstract][Full Text] [Related]
12. Oxadiazole-diarylpyrazole 4-carboxamides as cannabinoid CB1 receptor ligands.
Lee SH; Seo HJ; Kim MJ; Kang SY; Song KS; Lee SH; Jung ME; Kim J; Lee J
Bioorg Med Chem Lett; 2009 Apr; 19(7):1899-902. PubMed ID: 19269817
[TBL] [Abstract][Full Text] [Related]
13. 1-Aryl-5-(1H-pyrrol-1-yl)-1H-pyrazole-3-carboxamide: an effective scaffold for the design of either CB1 or CB2 receptor ligands.
Piscitelli F; Ligresti A; La Regina G; Gatti V; Brizzi A; Pasquini S; Allarà M; Carai MA; Novellino E; Colombo G; Di Marzo V; Corelli F; Silvestri R
Eur J Med Chem; 2011 Nov; 46(11):5641-53. PubMed ID: 21996466
[TBL] [Abstract][Full Text] [Related]
14. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse.
Fride E; Braun H; Matan H; Steinberg S; Reggio PH; Seltzman HH
Pediatr Res; 2007 Nov; 62(5):533-6. PubMed ID: 17805201
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
[TBL] [Abstract][Full Text] [Related]
17. Diaryl dihydropyrazole-3-carboxamides with significant in vivo antiobesity activity related to CB1 receptor antagonism: synthesis, biological evaluation, and molecular modeling in the homology model.
Srivastava BK; Joharapurkar A; Raval S; Patel JZ; Soni R; Raval P; Gite A; Goswami A; Sadhwani N; Gandhi N; Patel H; Mishra B; Solanki M; Pandey B; Jain MR; Patel PR
J Med Chem; 2007 Nov; 50(24):5951-66. PubMed ID: 17979261
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationship of 1,2,4-triazole-containing diarylpyrazolyl carboxamide as CB1 cannabinoid receptor-ligand.
Seo HJ; Kim MJ; Lee SH; Lee SH; Jung ME; Kim MS; Ahn K; Kim J; Lee J
Bioorg Med Chem; 2010 Feb; 18(3):1149-62. PubMed ID: 20045337
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.
Janero DR; Makriyannis A
Expert Opin Emerg Drugs; 2009 Mar; 14(1):43-65. PubMed ID: 19249987
[TBL] [Abstract][Full Text] [Related]
20. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
Hurst D; Umejiego U; Lynch D; Seltzman H; Hyatt S; Roche M; McAllister S; Fleischer D; Kapur A; Abood M; Shi S; Jones J; Lewis D; Reggio P
J Med Chem; 2006 Oct; 49(20):5969-87. PubMed ID: 17004712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
